Table 2.

The maximal vasorelaxant responses and potency of CBD in human mesenteric arteries

		Vehicle	CBD	n
	Rmax	10.2 ± 3.5	39.2 ± 4.0 ****
	EC50	−4.98 ± 0.87	−5.14 ± 0.21	12
		Control CBD	Intervention	n
Minus endothelium	Rmax	51.6 ± 2.8	44.6 ± 3.8
	EC50	−5.84 ± 0.18	−5.21 ± 0.18 ****	8
L-NAME	Rmax	51.4 ± 4.9	39.1 ± 6.6
	EC50	−5.39 ± 0.26	−5.24 ± 0.35	6
Indomethacin	Rmax	50.4 ± 4.0	55.2 ± 4.6
	EC50	−5.82 ± 0.26	−5.26 ± 0.20	6
KPSS contracted	Rmax	49.7 ± 5.8	8.9 ± 2.4 ***
	EC50	−5.45 ± 0.30	−5.59 ± 0.73	5
AM251	Rmax	53.9 ± 3.7	24.2 ± 4.9 ***
	EC50	−5.57 ± 0.19	−5.53 ± 0.49	9
LY320135	Rmax	45.0 ± 3.5	30.2 ± 5.4 *
	EC50	−5.83 ± 0.24	−5.88 ± 0.54	6
AM630	Rmax	58.7 ± 3.9	59.5 ± 5.5
	EC50	−5.56 ± 0.17	−5.48 ± 0.23	8
Capsaicin pre-treatment	Rmax	47.7 ± 2.4	21.3 ± 3.9 ****
	EC50	−5.92 ± 0.15	−5.85 ± 0.39	7
O-1918	Rmax	51.8 ± 2.8	43.8 ± 3.9
	EC50	−5.68 ± 0.16	−5.61 ± 0.26	7

Sigmoidal concentration-response curves to CBD were fitted using Prism and R_max and EC₅₀ values were compared by Student's t test (with Welch's correction for groups with unequal standard deviations).